Marker Therapeutics Files Definitive Proxy Statement

TL;DR

Marker Therapeutics proxy filing is out - time to vote on directors and company matters.

AI Summary

Marker Therapeutics, Inc. filed its definitive proxy statement on February 4, 2025, for its annual meeting. The filing concerns the solicitation of proxies for the election of directors and other corporate matters. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is based in Houston, TX.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including director elections and proposals, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new business risks.

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Registrant
• TAPIMMUNE INC. (company) — Former Company Name
• GENEMAX CORP (company) — Former Company Name
• 20250204 (date) — Filing Date
• 20250321 (date) — Period of Report

FAQ

Key Financial Figures

• $0.001 — 83,805 shares of Common Stock par value $0.001 per share (the " Common Stock "), (ii)
• $16.1 m — he Private Placement were approximately $16.1 million, before deducting placement agent
• $4.00 — ment Warrants have an exercise price of $4.00 per share. The Warrants provide for a
• $5 million — Fee Investors "), (ii) 3% of the first $5 million of aggregate gross proceeds of the Priv

Filing Documents

• tm253006-2_def14a.htm (DEF 14A) — 153KB
• lg_markertherapeutics-4clr.jpg (GRAPHIC) — 31KB
• px_24markerthepy01pg01-4c.jpg (GRAPHIC) — 289KB
• px_24markerthepy01pg02-4c.jpg (GRAPHIC) — 136KB
• px_24markerthepy01pg03-4c.jpg (GRAPHIC) — 159KB
• 0001104659-25-009098.txt ( ) — 967KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 9 HOUSEHOLDING OF PROXY MATERIALS 10 OTHER MATTERS 11 i TABLE OF CONTENTS MARKER THERAPEUTICS, INC. 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251 Houston, TX 77021 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS MARCH 21, 2025 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why am I receiving these materials? We have sent you these proxy materials because the Board of Directors (the "Board" or "Board of Directors") of Marker Therapeutics, Inc. (sometimes referred to as the "Company" or "Marker") is soliciting your proxy to vote at the Special Meeting of Stockholders, including at any adjournments or postponements of the meeting. You are invited to attend the Special Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy over the telephone or through the internet. We intend to mail these proxy materials on or about February 4, 2025, to all stockholders of record entitled to vote at the Special Meeting. How do I attend the Special Meeting? The Special Meeting will be a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. In order to attend the Special Meeting, you must first register at https://web.viewproxy.com/markertherapeutics/2025SM by 11:59 p.m. Eastern Time on Thursday, March 20, 2025. Please follow the instructions on the registration page. You will then receive a meeting invitation by email with your unique link to join the Special Meeting along with a password prior to the meeting date. We recommend that you log on a few minutes before the Special Meeting to ensure that you are logged in when the meeting begins. Information on how to vote online duri

View Full Filing

View this DEF 14A filing on SEC EDGAR